Table 2. Clinical and virological characteristics of HBV/HIV co-infected patients (n = 17).

ID	Age/sex	HBV genotype	CD4+ T cella	PLT count	Anti-HBV agent	ART durationb	DR Mutations	WHO stage
HP14	49/M	-	730	531	3TC	7	-	I
HP22	38/M	A	224	134	3TC	6	rtV173L, rtL180M,rtM204V	I
HP32	60/F	A	583	260	TDF, 3TC	3	rtV173L, rtL180M,rtM204V	I
HP51	37/F	A	493	355	3TC	8	rtV173L, rtL180M,rtM204V	I
HP64	52/M	A	209	222	TDF, 3TC	4	rtL180M	I
HP82	39/M	E	83	234	TDF, 3TC	6	WT	I
HP95	40/F	E	640	265	3TC	3	rtV173L, rtL180M,rtM204V	I
HP106	39/M	-	712	147	3TC	9	-	I
HP113	39/F	C	483	278	3TC	8	rtV173L, rtL180M,rtM204V	I
HP123	28/M	A	206	92	3TC	5	rtV173L, rtL180M,rtM204V	I
HP141	24/F	A	125	272	TDF, 3TC	2	WT	I
HP169	37/F	D	390	377	3TC	9	WT	I
HP193	43/M	-	262	184	3TC	10	-	I
HP248	30/F	G	619	211	3TC	5	WT	III
HP258	35/M	A	666	305	3TC	2	WT	I
HP259	35/M	-	1065	234	TDF, 3TC	3	-	I
HP268	39/F	D	593	388	3TC	7	WT	I

3TC, Lamivudine; TDF, Tenofovir, PLT, Platelets count (x 10³/mL); DR, drug resistance;

^aCD4+T cell count (Cell/μl);

^b ART duration (in year)